CDH11 and breast cancer: To more formally test the association of CDH11 with poor prognosis malignancies we first carried out a meta-analysis of all published datasets to show that in addition to being elevated in early stages of breast cancer such as ductal carcinoma in-situ (DCIS), CDH11 is highly expressed in gastrointestinal, brain and central nervous system tumors.